1. Scrip
  2. >>R&D

Coronavirus Update: How Vaccines Stack Up Against Variants So Far

Boehringer Ingelheim Drops ARDS Drug

 
• By Scrip Team

Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.

Novavax Trial US
Novavax's vaccine showed greater than 55% efficacy against the South African B.1.351 variant • Source: Shutterstock

On 11 March, Novavax, Inc. said its investigational protein-based COVID-19 vaccine, NVX-CoV2373, demonstrated high levels of efficacy against both the original SARS-CoV-2 strain – 96.4% – and the B.1.1.7 strain that originated in the UK, with an efficacy level of 86.3%.

But the bigger question is how it will fare against newer strains, particularly the South African B.1.351 variant, which has shown an ability to evade vaccine-derived immunity. (Also see "

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.